Engflag

Nor-Tripar

Quick links to important sections

Nor-Tripar

Nor-Tripar_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nor-Tripar

Quick Facts

Property Description
Active Ingredient Nitazoxanide
Form Tablet and Oral Suspension
Pharmacological Class Antiprotozoal and Antiparasitic Agent
General Purpose Elimination of parasitic and protozoal invaders
Origin Synthetic (Thiazolide class)

Nor-Tripar: Core Definition and Pharmacological Classification

Nor-Tripar is the specific commercial name for a prescription-only medicine containing the active ingredient Nitazoxanide, a synthetic compound with broad-spectrum antiprotozoal properties. Nitazoxanide is categorized as an antiprotozoal agent, meaning its core function is to counter infections caused by single-celled parasites. This drug belongs to the unique thiazolide chemical class, which is recognized for its structural novelty in treating protozoal infections. Nor-Tripar's use of Nitazoxanide identifies it as a broad-spectrum antiparasitic agent suitable for both adults and pediatric patients.

Composition, Forms, and Origin of Nitazoxanide

The active medicinal substance is exclusively Nitazoxanide, confirming this preparation as a single-active ingredient product intended for oral administration. To accommodate various patient needs, particularly in the pediatric patient group, the medicine is available in two physical preparations: a solid, film-coated tablet and an oral suspension (liquid form), both of which deliver the active compound. The synthetic compound's structure is derived from a nitrothiazole benzamide chemical scaffold, highlighting its non-natural, laboratory origin. This dual-form availability is a key feature that aids in therapeutic application across different age groups.

General Therapeutic Function of the Broad-Spectrum Agent

The general purpose of this medicine is to help the body resolve infections by eliminating a wide variety of parasitic and protozoal invaders. Nitazoxanide acts as a broad-spectrum antiparasitic agent because its activity extends to both protozoa and specific helminths (parasitic worms). This thiazolide is used in the treatment of parasitic infections. Its therapeutic effect occurs when the drug is converted into its active metabolite, tizoxanide, which works by disrupting the anaerobic energy metabolism of the targeted organisms through interference with the essential PFOR enzyme system. This biological action means the drug stops the infectious agent from sustaining itself.

Regulatory References

  1. NIH Review of Thiazolides
  2. LiverTox Reference

What side effects are possible with Nor-Tripar?

Possible Side Effects and Safety Information

The safety profile for Nor-Tripar (Nitazoxanide) is officially documented by health authorities and is structured around reported adverse reactions categorized by frequency and the body system affected. These classifications are based on clinical trial data and postmarketing surveillance.

Common Adverse Reactions

Adverse reactions classified as Most Common (ge 2%) in clinical trials are primarily associated with the Gastrointestinal and Nervous System domains, as well as the Renal/Urogenital System.

System-Organ Class Most Common Adverse Reactions (Frequency ge 2%)
Gastrointestinal disorders Abdominal pain, Nausea
Nervous System disorders Headache
Renal/Urogenital System Chromaturia (Urine discoloration)

Events reported in the Postmarketing Experience, for which frequency is not reliably estimated, include diarrhea, dizziness, dyspnea (trouble breathing), rash, and urticaria (hives).

Safety Constraints and Special Populations

Serious Safety Restrictions officially documented include a contraindication against the medicine’s use in individuals with a known prior hypersensitivity reaction to nitazoxanide or any component of the formulation.

Specific Population-Specific Cautions exist due to gaps in regulatory data. The medicine's safety has not been studied in patients with compromised renal or hepatic function. Caution is advised for use in individuals with existing hepatic, biliary, or renal disease. Additionally, the official label notes that efficacy has not been established for treating diarrhea caused by Cryptosporidium parvum in immunodeficient populations (e.g., HIV-infected individuals).

Furthermore, caution is warranted when the medicine is co-administered with other highly plasma protein-bound medications that possess a narrow therapeutic index.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information details the officially documented signs of Nor-Tripar (Nitazoxanide) overdose and the regulator-mandated actions required for emergency response, based strictly on government-authorized prescribing information.

Documented Clinical Manifestations

The most common clinical manifestations of acute human overdose are generally self-limited and confined to the gastrointestinal system. Official regulatory documents list the observed symptoms as nausea, vomiting, and abdominal pain.

No specific severe, life-threatening, or unique neurological or cardiovascular complications have been explicitly documented in official regulatory summaries as a direct consequence of acute overdose.

Emergency Actions and Treatment

In the event of a suspected or known overdose, immediate medical attention is required. The official mandate is to contact a Poison Control Center immediately for advice and to seek emergency services for evaluation.

No specific antidote is known for Nor-Tripar overdose. Consequently, the formal procedure for managing an overdose is strictly limited to providing symptomatic and supportive treatment. This includes close medical observation and management of any clinical signs or symptoms as they arise, ensuring the patient receives necessary medical support.

Therapeutic Uses of Nor-Tripar

The primary therapeutic domain for Nor-Tripar (Nitazoxanide) is for use in situations involving certain distressing symptoms. The medication is utilized in areas where additional symptomatic support is needed for managing symptoms linked to specific parasitic infections. It is considered relevant for easing symptoms related to physical discomfort caused by Giardia lamblia or Cryptosporidium parvum.

The drug is commonly used to help with conditions characterized by periods of heightened symptoms, such as persistent diarrhea, which can interfere with daily functioning. In clinical contexts, this medication supports the patient during difficult episodes by easing the overall symptom burden. This treatment may assist with maintaining functional stability in patients experiencing acute or disruptive symptom patterns. The use of this medication generally contributes to improved day-to-day comfort during symptomatic periods and is relevant when supportive symptom management is appropriate.

Quick Fact: Relevant for Easing Symptoms of Diarrhea

Eligibility and Restrictions for Use

Eligibility for Nor-Tripar: Official Regulatory Status

Nor-Tripar (Nitazoxanide) use is governed by official population eligibility rules defined by regulatory authorities.

Category Regulatory Status Description
Absolute Contraindication Contraindicated Patients with known hypersensitivity to nitazoxanide or any component of the formulation.
Tablet Age Restriction Must not be administered Pediatric patients 11 years of age or younger are not eligible for the tablet form.

Eligibility is defined by age group and formulation:

  • The oral suspension is approved for pediatric patients 1 year of age and older.
  • The tablet form is approved for patients 12 years of age and older.
  • Safety and efficacy are not established for the oral suspension in children less than one year of age.

Condition-Based Restrictions

Certain conditions require special regulatory consideration:

  • Immunodeficiency: The drug has not been shown to be effective for treating C. parvum in HIV-infected or immunodeficient patients.
  • Organ Function: Use requires caution in patients with impaired renal (kidney) or hepatic (liver) function, as specific pharmacokinetic studies are lacking in these groups.
  • Pregnancy and Lactation: No human data is available to inform a drug-associated risk in pregnant women. No information is available regarding the presence of the drug in human milk; caution is recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Nor-Tripar (Nitazoxanide) possesses a specific interaction profile documented in government regulatory labeling. The medicine is formally contraindicated only in individuals with a known prior hypersensitivity to nitazoxanide or any of its formulation components.

The most significant documented drug interaction pattern is based on plasma protein binding. The active metabolite of Nor-Tripar, tizoxanide, is highly protein-bound (over 99.9%). Co-administration with other highly plasma protein-bound medicines that have narrow therapeutic indices may result in competition for these binding sites. Warfarin, an example of such a medicine, is explicitly noted in official labeling. For these combinations, regulatory documents require patient monitoring for adverse reactions related to the highly protein-bound co-administered drug.

The regulatory profile addresses enzyme-based interactions by noting that no significant interaction is expected when Nor-Tripar is used with other medicines that are either metabolized by or inhibit CYP450 enzymes.

Regarding non-medicinal substances, official labeling indicates that co-administration with food is required as it substantially increases the oral bioavailability of Nor-Tripar. Furthermore, the pharmacokinetics of Nor-Tripar have not been studied in individuals with compromised renal or hepatic function, a factor which must be considered during its use.

Mechanism of Action

Interference with Parasite Anaerobic Energy Metabolism

The drug's active metabolite, Tizoxanide, functions as a noncompetitive inhibitor of the Pyruvate:ferredoxin oxidoreductase (PFOR) enzyme. This enzyme is essential for the parasite's anaerobic energy synthesis, and its inhibition immediately blocks the electron transfer process required for generating ATP. This targeted disruption causes a rapid and irreversible metabolic collapse in susceptible protozoa, which ultimately leads to their cellular death.

Modulation of Helminth Neural Signaling

Nor-Tripar also exerts a distinct mechanism against certain parasitic worms (helminths) by modulating specific neurological targets, notably Glutamate-Gated Chloride Ion Channels. This molecular interference disrupts the worm's nervous system function and its ability to control muscle activity. The resulting functional compromise and immobilization of the helminth occurs as a direct consequence of this action.

Constraints of the Activation-Dependent Mechanism

The mechanism is contingent on the infectious organism possessing the necessary nitroreductase enzymes to process the parent compound into the active metabolite, Tizoxanide. Consequently, the drug's action is constrained by the potential for genetic mutations in the parasite that could weaken this enzyme's function or reduce drug binding to the PFOR target, which would limit the extent of cellular death.

Dosage and Administration Information

How to Use Nor-Tripar: Administration Guidelines

Nor-Tripar (Nitazoxanide) is administered through a precise, fixed-course oral regimen that is dependent on patient age and must be taken with food.

Administration Scope

Instruction Category Standard Protocol
Route of Administration The method of use is oral administration for both the tablet and the oral suspension forms.
Dosing Schedule 500 mg per dose for adults and pediatric patients age 12 years and older. 200 mg for 4 to 11 years, and 100 mg for 1 to 3 years.
Timing in Relation to Meals Administration is conducted with food to support proper absorption of the active metabolite.
Preparation Requirements The oral suspension powder requires reconstitution with a specific volume of water, added in portions with vigorous shaking. The suspension must be shaken well immediately before each use.
Age-Group Administration The 500 mg tablet is for patients age 12 years and older. Children 1 to 11 years use the oral suspension.
Missed-Dose Rules If a dose is missed, the next scheduled dose is taken with food at the regular time. Two doses should not be taken at the same time to make up for a missed dose.

Procedural Structure

The full course of therapy is a fixed duration of 3 days, with a twice-daily frequency (every 12 hours). The tablet and oral suspension forms are not bioequivalent and are used according to age-specific dosing requirements. This structured approach, defined by the specific dosage, timing with food, and duration, constitutes the established procedure for using the medicine.

Recent Clinical Evidence

Evidence for Use in Diarrhea due to Giardiasis

Research for this indication primarily involved short-term Randomized Controlled Trials (RCTs) and systematic reviews that evaluated Nor-Tripar in immune-competent adults and children. These studies focused on two main outcomes: parasite clearance verified by stool examination and clinical response monitoring the resolution of diarrhea. Findings described data points related to the observed populations during the short treatment period. However, long-term effects are not fully established, and evidence for immunocompromised patients remains limited.

Evidence for Use in Diarrhea due to Cryptosporidiosis

Nor-Tripar was studied for this condition in trials primarily comparing it to a placebo. Research examined outcomes related to both parasitological cure (oocyst clearance) and clinical response in immune-competent patients. A critical observation was made in trials involving immunocompromised individuals (such as HIV-positive patients), where the measured outcomes were comparable to those in the placebo group. This indicates a key limitation in the research for this specific population.

Long-Term Studies and Evidence Gaps

The clinical evidence gathered so far mainly consists of research exploring short-term symptom changes over defined time intervals. Most follow-up durations were limited, typically ending within a few days post-treatment. Therefore, long-term effects are not fully established, and there is limited information on the durability of parasite clearance or relapse prevention. Furthermore, Data for certain groups remain insufficient, including the performance against parasite strains that may be resistant to treatment.

How should Nor-Tripar be stored and disposed of?

How to Store and Dispose of Nor-Tripar (Nitazoxanide)

Official regulations strictly define the storage and disposal requirements for Nor-Tripar. Both the tablets and the dry powder for oral suspension must be stored at Controlled Room Temperature, specifically 25 C (77 F), with limited temperature excursions permitted. The container must be kept tightly closed and protected from excess heat and moisture.

Stability and Handling

After the oral suspension is mixed, it must not be refrigerated and remains stable for only 7 days. Any unused portion of the liquid medicine must be discarded after this stability period. The medicine must always be stored out of the reach of children. Final disposal of expired or unneeded medicine should follow local regulations and official guidance, typically utilizing drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Nor-Tripar found in:

A-Z Index: